Nivalis Therapeutics

General Information

We are a clinical stage pharmaceutical company committed to the discovery, development and commercialization of product candidates for patients with cystic fibrosis, or CF. Our lead product candidate, N91115, is a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator, or CFTR, resulting from mutations in the CFTR gene, the underlying cause of CF. We believe N91115 is a first-in-class CFTR stabilizer that modulates CFTR activity through GSNOR inhibition, which is a novel mechanism of action that we expect to be complementary to existing and future CFTR modulators. N91115 is the only clinical stage product candidate we know of designed to stabilize CFTR inside the cell and at the cell surface. We have shown in preclinical studies that the stabilizing effect of N91115 significantly increases and prolongs CFTR activity when added to other CFTR modulators.

Employees: 23
Founded: 2007
Contact Information
Address 3122 Sterling Circle, Suite 200, Boulder, CO 80301, US
Phone Number (720) 945-7700
Web Address
View Prospectus: Nivalis Therapeutics
Financial Information
Market Cap $204.8mil
Revenues $0.0 mil (last 12 months)
Net Income $-9.6 mil (last 12 months)
IPO Profile
Symbol NVLS
Exchange NASDAQ
Shares (millions): 5.5
Price range $14.00 - $14.00
Est. $ Volume $77.0 mil
Manager / Joint Managers Cowen and Company/ Stifel
CO-Managers Baird/ H.C. Wainwright
Expected To Trade: 6/17/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change